Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (10) 10
humans (8) 8
hematology (7) 7
multiple myeloma (6) 6
oncology (6) 6
transplantation (6) 6
animals (5) 5
mice (5) 5
abridged index medicus (4) 4
cancer (4) 4
chemotherapy (4) 4
health aspects (4) 4
in-vivo (4) 4
risk factors (4) 4
adult (3) 3
aged (3) 3
article (3) 3
female (3) 3
gene expression (3) 3
gene-expression (3) 3
genetic aspects (3) 3
male (3) 3
medicine, research & experimental (3) 3
mice, inbred c57bl (3) 3
middle aged (3) 3
multiple myeloma - drug therapy (3) 3
mutation (3) 3
research (3) 3
research article (3) 3
stem cells (3) 3
acute myeloid-leukemia (2) 2
aged, 80 and over (2) 2
base sequence (2) 2
blotting, western (2) 2
bone (2) 2
bone marrow - pathology (2) 2
boronic acids - administration & dosage (2) 2
bortezomib (2) 2
care and treatment (2) 2
cell proliferation - drug effects (2) 2
cells (2) 2
complications and side effects (2) 2
differentiation (2) 2
expression (2) 2
gene mutations (2) 2
hemic and lymphatic diseases (2) 2
immunology (2) 2
leukemia, myeloid, acute - genetics (2) 2
molecular sequence data (2) 2
multiple myeloma - metabolism (2) 2
multiple myeloma - pathology (2) 2
myelodysplastic syndromes (2) 2
myelodysplastic syndromes - genetics (2) 2
pyrazines - administration & dosage (2) 2
survival (2) 2
survival analysis (2) 2
therapy (2) 2
usage (2) 2
5-aza-2'-deoxycytidine (1) 1
5-methylcytosine - analysis (1) 1
activation (1) 1
acute myeloid leukemia (1) 1
administration, oral (1) 1
alpha-v-beta-3 integrin (1) 1
analysis (1) 1
angiogenesis (1) 1
anthracyclines (1) 1
anthropometric characteristics (1) 1
antimetabolites, antineoplastic - administration & dosage (1) 1
antimetabolites, antineoplastic - adverse effects (1) 1
antineoplastic combined chemotherapy protocols - therapeutic use (1) 1
apoptosis - drug effects (1) 1
au-rich element (1) 1
auto-sct (1) 1
azacitidine - administration & dosage (1) 1
azacitidine - adverse effects (1) 1
azacitidine - analogs & derivatives (1) 1
basic helix-loop-helix leucine zipper transcription factors - chemistry (1) 1
basic helix-loop-helix leucine zipper transcription factors - metabolism (1) 1
bcl-2 proteins (1) 1
beta-3-integrin (1) 1
bh3 mimetic abt-737 (1) 1
biocompatibility (1) 1
biomarkers (1) 1
biomarkers, tumor - analysis (1) 1
blast-crisis (1) 1
blood diseases (1) 1
body-mass index (1) 1
bone lesions (1) 1
bone marrow (1) 1
bone marrow - chemistry (1) 1
bone marrow - drug effects (1) 1
bone marrow - metabolism (1) 1
bone resorption - drug therapy (1) 1
bone resorption - etiology (1) 1
bone-marrow (1) 1
boronic acids - adverse effects (1) 1
breast-cancer (1) 1
c-myc (1) 1
c-myc/max dimerization (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes
by Welch, John S and Petti, Allegra A and Miller, Christopher A and Fronick, Catrina C and O’Laughlin, Michelle and Fulton, Robert S and Wilson, Richard K and Baty, Jack D and Duncavage, Eric J and Tandon, Bevan and Lee, Yi-Shan and Wartman, Lukas D and Uy, Geoffrey L and Ghobadi, Armin and Tomasson, Michael H and Pusic, Iskra and Romee, Rizwan and Fehniger, Todd A and Stockerl-Goldstein, Keith E and Vij, Ravi and Oh, Stephen T and Abboud, Camille N and Cashen, Amanda F and Schroeder, Mark A and Jacoby, Meagan A and Heath, Sharon E and Luber, Kierstin and Janke, Megan R and Hantel, Andrew and Khan, Niloufer and Sukhanova, Madina J and Knoebel, Randall W and Stock, Wendy and Graubert, Timothy A and Walter, Matthew J and Westervelt, Peter and Link, Daniel C and DiPersio, John F and Ley, Timothy J
The New England Journal of Medicine, ISSN 0028-4793, 11/2016, Volume 375, Issue 21, pp. 2023 - 2036
Decitabine produced responses in patients with acute myeloid leukemia or myelodysplastic syndromes who had cytogenetic abnormalities associated with a poor... 
HYPOMETHYLATING AGENTS | MEDICINE, GENERAL & INTERNAL | THERAPY | RESPONSE CRITERIA | DNA METHYLATION | OLDER PATIENTS | TET2 MUTATIONS | CLONAL HEMATOPOIESIS | IN-VIVO | COMPLEX KARYOTYPE | INTERNATIONAL WORKING GROUP | Azacitidine - adverse effects | Prospective Studies | Humans | Middle Aged | Male | Tumor Suppressor Protein p53 - genetics | Antimetabolites, Antineoplastic - administration & dosage | Exome | Bone Marrow - chemistry | Aged, 80 and over | Leukemia, Myeloid, Acute - drug therapy | Adult | Female | Myelodysplastic Syndromes - drug therapy | Azacitidine - administration & dosage | 5-Methylcytosine - analysis | Biomarkers, Tumor - analysis | Risk Factors | Azacitidine - analogs & derivatives | Survival Rate | Leukemia, Myeloid, Acute - mortality | Bone Marrow - pathology | Antimetabolites, Antineoplastic - adverse effects | Myelodysplastic Syndromes - mortality | Aged | Myelodysplastic Syndromes - genetics | Mutation | Leukemia, Myeloid, Acute - genetics | Care and treatment | Research | Tumor proteins | Myelodysplastic syndromes | Myeloid leukemia | p53 Protein | Leukemia | Survival | Myelodysplastic syndrome | Risk factors | Clinical outcomes | Chemotherapy | Bone marrow | Biomarkers | Blood diseases | Acute myeloid leukemia | 5-aza-2'-deoxycytidine
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text The epoxyketone-based proteasome inhibitors carfilzomib and orally bioavailable oprozomib have anti-resorptive and bone-anabolic activity in addition to anti-myeloma effects
by Hurchla, M.A and Garcia-Gomez, A and Hornick, M.C and Ocio, E.M and Li, A and Blanco, J.F and Collins, L and Kirk, C.J and Piwnica-Worms, D and Vij, R and Tomasson, M.H and Pandiella, A and San Miguel, J.F and Garayoa, M and Weilbaecher, K.N
Leukemia, ISSN 0887-6924, 02/2013, Volume 27, Issue 2, pp. 430 - 440
Proteasome inhibitors (Pis), namely bortezomib, have become a cornerstone therapy for multiple myeloma (MM), potently reducing tumor burden and inhibiting... 
MULTIPLE-MYELOMA | CELLS | multiple myeloma | ACTIVATION | OSTEOBLAST DIFFERENTIATION | TGF-BETA | proteasome inhibitors | osteoblast | BORTEZOMIB | MURINE MODEL | UNFOLDED PROTEIN RESPONSE | ONCOLOGY | bone lesions | IN-VIVO | osteoclast | HEMATOLOGY | IRREVERSIBLE INHIBITOR | Stromal Cells - pathology | Humans | Pyrazines - administration & dosage | Multiple Myeloma - drug therapy | Epoxy Compounds - pharmacology | Bone Marrow - metabolism | Stromal Cells - drug effects | Boronic Acids - administration & dosage | Tumor Cells, Cultured | Real-Time Polymerase Chain Reaction | Bone Marrow - drug effects | Tumor Microenvironment - drug effects | Bone Resorption - etiology | Osteoclasts - pathology | Bortezomib | Calcification, Physiologic - drug effects | Administration, Oral | Multiple Myeloma - complications | Mice, Inbred C57BL | Osteoblasts - drug effects | Osteogenesis - drug effects | RNA, Messenger - genetics | Stromal Cells - metabolism | Bone Resorption - drug therapy | Mice, SCID | Reverse Transcriptase Polymerase Chain Reaction | Blotting, Western | Proteasome Inhibitors - therapeutic use | Osteoblasts - pathology | Animals | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Cell Differentiation - drug effects | Bone Marrow - pathology | Mice, Inbred NOD | Cell Proliferation - drug effects | Mice | Oligopeptides - administration & dosage | Osteoclasts - drug effects | Usage | Enzyme inhibitors | Multiple myeloma | Carfilzomib | Drug therapy | Health aspects
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text NEK2 induces osteoclast differentiation and bone destruction via heparanase in multiple myeloma
by Hao, M and Franqui-Machin, R and Xu, H and Shaughnessy, J and Barlogie, B and Roodman, D and Quelle, D.E and Janz, S and Tomasson, M.H and Sanderson, R.D and Qiu, L and Frech, I and Tricot, G and Zhan, F
Leukemia, ISSN 0887-6924, 07/2017, Volume 31, Issue 7, pp. 1648 - 1650
ONCOLOGY | HEMATOLOGY | PROGNOSIS | EXPRESSION | CELL | Osteoclastogenesis | Biocompatibility | Bone | Destruction | Differentiation | Multiple myeloma | Letter to the Editor
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text The skinny on obesity and plasma cell myeloma: A review of the literature
by Carson, K.R and Bates, M.L and Tomasson, M.H
Bone Marrow Transplantation, ISSN 0268-3369, 2014, Volume 49, Issue 8, pp. 1009 - 1015
Despite tremendous advances in treatments for myeloma in the past decade, the disease remains incurable in the majority of patients. Here, we review recent... 
WEIGHT-LOSS | IMMUNOLOGY | TRANSPLANTATION | BREAST-CANCER | ONCOLOGY | BODY-MASS INDEX | NON-HODGKIN-LYMPHOMA | PHYSICAL-ACTIVITY | ANTHROPOMETRIC CHARACTERISTICS | MONOCLONAL GAMMOPATHY | SMOLDERING MULTIPLE-MYELOMA | HEMATOLOGY | GROWTH-FACTOR-I | UNDETERMINED SIGNIFICANCE MGUS | Multiple Myeloma - epidemiology | Precancerous Conditions - etiology | Multiple Myeloma - etiology | Precancerous Conditions - epidemiology | Obesity - complications | Humans | Obesity - epidemiology | Risk Factors | Precancerous Conditions - metabolism | Multiple Myeloma - metabolism | Obesity - metabolism | Obesity | Complications and side effects | Evaluation | Multiple myeloma | Medicine, Preventive | Risk factors | Preventive health services
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Sn2 lipase labile prodrugs and contact-facilitated drug delivery for lipid-encapsulated nanomedicines
by Pan, D and Cui, G and Pham, C.T.N and Tomasson, M.H and Weilbaecher, K.N and Lanza, G.M
ACS Symposium Series, ISSN 0097-6156, 2017, Volume 1271, pp. 189 - 209
Conference Proceeding
Details down arrow
6. Full Text Bortezomib administered pre-auto-SCT and as maintenance therapy post transplant for multiple myeloma: a single institution phase II study
by Uy, G.L and Goyal, S.D and Fisher, N.M and Oza, A.Y and Tomasson, M.H and Stockerl-Goldstein, K and DiPersio, J.F and Vij, R
Bone Marrow Transplantation, ISSN 0268-3369, 05/2009, Volume 43, Issue 10, pp. 793 - 800
The appropriate induction therapy before and the role of maintenance therapy after auto-SCT for patients with multiple myeloma remain areas of active... 
stem cell mobilization | multiple myeloma | LENALIDOMIDE PLUS DEXAMETHASONE | auto-SCT | IMPROVES SURVIVAL | THALIDOMIDE | IMMUNOLOGY | COMBINATION | VERSUS-HOST-DISEASE | CHEMOTHERAPY | RANDOMIZED TRIAL | TRANSPLANTATION | INTERFERON | ONCOLOGY | PROTEASOME INHIBITOR BORTEZOMIB | bortezomib | STEM-CELL TRANSPLANTATION | HEMATOLOGY | Peripheral Blood Stem Cell Transplantation - methods | Humans | Middle Aged | Pyrazines - administration & dosage | Boronic Acids - adverse effects | Male | Transplantation, Autologous | T-Lymphocytes, Cytotoxic - drug effects | Herpesvirus 3, Human - drug effects | Multiple Myeloma - drug therapy | Multiple Myeloma - therapy | Adult | Female | Boronic Acids - administration & dosage | Hematopoietic Stem Cell Mobilization | Bortezomib | Treatment Outcome | Remission Induction | Melphalan - administration & dosage | Virus Activation - drug effects | Lymphocyte Subsets | Pyrazines - adverse effects | Survival Analysis | Aged | Killer Cells, Natural - drug effects | Granulocyte Colony-Stimulating Factor - administration & dosage | Care and treatment | Patient outcomes | Multiple myeloma | Stem cells | Dosage and administration | Transplantation | Health aspects | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text High rates of reactivation of varicella zoster virus (VZV) associated with bortezomib (VELCADE) when given pre and post high dose chemotherapy (HDCT)
by Peles, S and Uy, G.L and Fisher, N.M and Tomasson, M.H and DiPersio, J.F and Vij, R
Biology of Blood and Marrow Transplantation, ISSN 1083-8791, 2006, Volume 12, Issue 2, pp. 116 - 117
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Bortezomib prior to autologous transplant in multiple myeloma: Effects on mobilization, engraftment, and markers of immune function
by Uy, G.L and Peles, S and Fisher, N.M and Tomasson, M.H and DiPersio, J.F and Vij, R
Biology of Blood and Marrow Transplantation, ISSN 1083-8791, 2006, Volume 12, Issue 2, pp. 116 - 116
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Bortezomib does not adversely affect stem cell mobilization and engraftment in patients with multiple myeloma undergoing autologous hematopoietic stem cell transplantation
by Uy, G.L and Fisher, N.M and Devine, S.M and Adkins, D.R and Tomasson, M.H and Graubert, T.A and DiPersio, J.F and Vij, R
Biology of Blood and Marrow Transplantation, ISSN 1083-8791, 2005, Volume 11, Issue 2, pp. 77 - 77
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Antagonizing Integrin beta 3 Increases Immunosuppression in Cancer
by Su, XM and Esser, AK and Amend, SR and Xiang, JY and Xu, YL and Ross, MH and Fox, GC and Kobayashi, T and Steri, V and Roomp, K and Fontana, F and Hurchla, MA and Knolhoff, BL and Meyer, MA and Morgan, EA and Tomasson, JC and Novack, JS and Zou, W and Faccio, R and Novack, DV and Robinson, SD and Teitelbaum, SL and DeNardo, DG and Schneider, JG and Weilbaecher, KN
CANCER RESEARCH, ISSN 0008-5472, 06/2016, Volume 76, Issue 12, pp. 3484 - 3495
Integrin beta 3 is critical for tumor invasion, neoangiogenesis, and inflammation, making it a promising cancer target. However, preclinical and clinical data... 
BETA-3-INTEGRIN | ANGIOGENESIS | ONCOLOGY | RANDOMIZED PHASE-II | NEWLY-DIAGNOSED GLIOBLASTOMA | MACROPHAGES | ALPHA-V-BETA-3 INTEGRIN | INHIBITOR CILENGITIDE | BONE | TUMOR-GROWTH | T-CELLS
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Full Text Impact of Chemotherapy Based Induction Using Dexamethasone, Cisplatin, Doxorubicin, Cyclophosphamide and Etoposide (DPACE) Versus Novel Agent Induction in Patients Undergoing Tandem Autologous Stem Cell Transplantation (ASCT) for Multiple Myeloma (MM)
by Nadiminti, Kalyan and Strouse, Christopher and Sidiqi, M Hasib and Dozeman, Lindsay and Mott, Sarah L and Schultz, Allyson and Claus, Jillna and Vikas, Praveen and Farooq, Umar and Tomasson, Michael and Silverman, Margarida and Jethava, Yogesh
Biology of Blood and Marrow Transplantation, ISSN 1083-8791, 03/2019, Volume 25, Issue 3, pp. S399 - S400
Many studies showed that novel agent based regimens result in superior response rates and depth. Recommended practice prior to ASCT in TE, NDMM is novel... 
Anthracyclines | Dexamethasone | Multiple myeloma | Etoposide | Transplantation | Cisplatin | Cyclophosphamide | Chemotherapy | Analysis | Central nervous system depressants | Stem cells | Steroids | Cancer
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
12. Full Text Mcl1 haploinsufficiency protects mice from Myc-induced acute myeloid leukemia
by Xiang, Zhifu and Luo, Hui and Payton, Jacqueline E and Cain, Jennifer and Ley, Timothy J and Opferman, Joseph T and Tomasson, Michael H
Journal of Clinical Investigation, ISSN 0021-9738, 06/2010, Volume 120, Issue 6, pp. 2109 - 2118
Antiapoptotic BCL2 family members have been implicated in the pathogenesis of acute myelogenous leukemia (AML), but the functional significance and relative... 
SURVIVAL | MEDICINE, RESEARCH & EXPERIMENTAL | STEM-CELLS | INDUCED APOPTOSIS | IN-VIVO | C-MYC | RESISTANCE | CHRONIC LYMPHOCYTIC-LEUKEMIA | BCL-2 PROTEINS | BH3 MIMETIC ABT-737 | EXPRESSION | Proteins - genetics | Proto-Oncogene Proteins c-bcl-2 - metabolism | Animals | Proteins - metabolism | Humans | Mice, Inbred C57BL | Myeloid Cell Leukemia Sequence 1 Protein | Mice | Mice, Inbred BALB C | Genes, bcl-2 | Proto-Oncogene Proteins c-bcl-2 - genetics | Leukemia, Myeloid, Acute - genetics | Haplotypes | Prevention | Myelocytic leukemia | Physiological aspects | Nonlymphoid leukemia | Gene expression | Identification and classification | Risk factors
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
13. Full Text Multiple myeloma-associated chromosomal translocation activates orphan snoRNA ACA11 to suppress oxidative stress
by Chu, Liang and Su, Mack Y and Maggi Jr, Leonard B and Lu, Lan and Mullins, Chelsea and Crosby, Seth and Huang, Gaofeng and Chng, Wee Joo and Vij, Ravi and Tomasson, Michael H
Journal of Clinical Investigation, ISSN 0021-9738, 08/2012, Volume 122, Issue 8, pp. 2793 - 2806
The histone methyltransferase WHSC1 (also known as MMSET) is overexpressed in multiple myeloma (MM) as a result of the t(4;14) chromosomal translocation and in... 
MEDICINE, RESEARCH & EXPERIMENTAL | LYSINE 36 | SYNDROME CANDIDATE 1 | WOLF-HIRSCHHORN SYNDROME | DNA-DAMAGE | GROWTH-FACTOR RECEPTOR-3 | T(4/14) TRANSLOCATION | GENE-EXPRESSION | NUCLEAR EXPORT | HISTONE METHYLTRANSFERASE | STATISTICAL-MODEL | Translocation, Genetic | Cell Proliferation | Oxidative Stress | Humans | DNA, Complementary - genetics | Molecular Sequence Data | Gene Expression Profiling | Chromosomes, Human, Pair 4 - genetics | RNA, Neoplasm - metabolism | Ribosomal Proteins - metabolism | RNA, Small Nucleolar - metabolism | Base Sequence | Nucleic Acid Conformation | Repressor Proteins - metabolism | RNA, Neoplasm - chemistry | Introns | Ribosomal Proteins - genetics | Multiple Myeloma - metabolism | RNA, Small Nucleolar - genetics | RNA, Small Nucleolar - chemistry | Multiple Myeloma - pathology | Animals | Histone-Lysine N-Methyltransferase - metabolism | Cell Transformation, Neoplastic | RNA, Neoplasm - genetics | Mice | DNA, Neoplasm - genetics | Chromosomes, Human, Pair 14 - genetics | Multiple Myeloma - genetics | Proteins | Genetic aspects | RNA | Multiple myeloma | Cancer
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
14. Full Text Small molecule MYC inhibitor conjugated to integrin-targeted nanoparticles extends survival in a mouse model of disseminated multiple myeloma
by Soodgupta, Deepti and Pan, Dipanjan and Cui, Grace and Senpan, Angana and Yang, Xiaoxia and Lu, Lan and Weilbaecher, Katherine N and Prochownik, Edward V and Lanza, Gregory M and Tomasson, Michael H
Molecular Cancer Therapeutics, ISSN 1535-7163, 06/2015, Volume 14, Issue 6, pp. 1286 - 1294
Multiple myeloma pathogenesis is driven by the MYC oncoprotein, its dimerization with MAX, and the binding of this heterodimer to E-Boxes in the vicinity of... 
VITRO | CELLS | THERAPY | ONCOLOGY | DRUG-DELIVERY | IN-VIVO | GENE-EXPRESSION | C-MYC/MAX DIMERIZATION | FUMAGILLIN PRODRUG | DIFFERENTIATION | CANCER | Small Molecule Libraries - pharmacology | Integrin alpha4beta1 - metabolism | Nanoparticles - chemistry | Apoptosis - drug effects | Humans | Small Molecule Libraries - metabolism | Integrin alphaVbeta3 - metabolism | Dose-Response Relationship, Drug | Multiple Myeloma - drug therapy | Disease Models, Animal | Integrin alphaVbeta3 - antagonists & inhibitors | Cell Survival - drug effects | Basic Helix-Loop-Helix Leucine Zipper Transcription Factors - chemistry | Proto-Oncogene Proteins c-myc - metabolism | Blotting, Western | Small Molecule Libraries - chemistry | Multiple Myeloma - pathology | Animals | Tumor Burden - drug effects | Integrin alpha4beta1 - antagonists & inhibitors | Proto-Oncogene Proteins c-myc - antagonists & inhibitors | Survival Analysis | Cell Line, Tumor | Basic Helix-Loop-Helix Leucine Zipper Transcription Factors - metabolism | Mice | Proto-Oncogene Proteins c-myc - chemistry | Prodrugs - pharmacology | Protein Multimerization - drug effects
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
15. Full Text Recurrent mutations in the U2AF1 splicing factor in myelodysplastic syndromes
by Graubert, Timothy A and Shen, Dong and Ding, Li and Okeyo-Owuor, Theresa and Lunn, Cara L and Shao, Jin and Krysiak, Kilannin and Harris, Christopher C and Koboldt, Daniel C and Larson, David E and McLellan, Michael D and Dooling, David J and Abbott, Rachel M and Fulton, Robert S and Schmidt, Heather and Kalicki-Veizer, Joelle and O'Laughlin, Michelle and Grillot, Marcus and Baty, Jack and Heath, Sharon and Frater, John L and Nasim, Talat and Link, Daniel C and Tomasson, Michael H and Westervelt, Peter and Dipersio, John F and Mardis, Elaine R and Ley, Timothy J and Wilson, Richard K and Walter, Matthew J
Nature Genetics, ISSN 1061-4036, 01/2012, Volume 44, Issue 1, pp. 53 - 57
Myelodysplastic syndromes (MDS) are hematopoietic stem cell disorders that often progress to chemotherapy-resistant secondary acute myeloid leukemia (sAML). We... 
MESSENGER-RNA | RECOGNITION | METHYLTRANSFERASE GENE EZH2 | SMALL-SUBUNIT | GENETICS & HEREDITY | ACUTE MYELOID-LEUKEMIA | DNMT3A MUTATIONS | IDENTIFICATION | AU-RICH ELEMENT | CANCER | GENOME | Humans | Middle Aged | Molecular Sequence Data | Male | Mutation, Missense | Disease Progression | Splicing Factor U2AF | RNA Splicing | Base Sequence | Aged, 80 and over | Adult | Female | Ribonucleoproteins - genetics | Aged | Myelodysplastic Syndromes - genetics | Nuclear Proteins - genetics | Chemotherapy | Pathogenesis | Genetics | Genomes | Mutation | Genetic testing | Gene expression | Cancer
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
16. Full Text Csf3r mutations in mice confer a strong clonal HSC advantage via activation of Stat5
by Liu, Fulu and Kunter, Ghada and Krem, Maxwell M and Eades, William C and Cain, Jennifer A and Tomasson, Michael H and Hennighausen, Lothar and Link, Daniel C
Journal of Clinical Investigation, ISSN 0021-9738, 03/2008, Volume 118, Issue 3, pp. 946 - 955
A fundamental property of leukemic stem cells is clonal dominance of the bone marrow microenvironment. Truncation mutations of CSF3R, which encodes the G-CSF... 
COLONY-STIMULATING-FACTOR | FACTOR-RECEPTOR | MEDICINE, RESEARCH & EXPERIMENTAL | BLAST-CRISIS | HEMATOPOIETIC STEM-CELLS | SEVERE CONGENITAL NEUTROPENIA | BONE-MARROW | GENE-EXPRESSION | SELF-RENEWAL | GRANULOCYTIC DIFFERENTIATION | ACUTE MYELOID-LEUKEMIA | Granulocyte Colony-Stimulating Factor - pharmacology | Animals | STAT3 Transcription Factor - physiology | Mice, Inbred C57BL | STAT5 Transcription Factor - physiology | Hematopoietic Stem Cells - physiology | Cell Proliferation - drug effects | Mice | Receptors, Granulocyte Colony-Stimulating Factor - genetics | Mutation | Neutropenia - congenital | Complications and side effects | Gene mutations | Stem cells | Genetic aspects | Research | Gene expression | Health aspects
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
17. Full Text Recurrent mutations in the U2AF1 splicing factor in myelodysplasia syndromes
by Graubert, Timothy A and Shen, Dong and Ding, Li and Okeyo-Owuor, Theresa and Lunn, Cara L and Shao, Jin and Krysiak, Kilannin and Harris, Christopher C and Koboldt, Daniel C and Larson, David E and McLellan, Michael D and Dooling, David J and Abbott, Rachel M and Fulton, Robert S and Schmidt, Heather and Kalicki-Veizer, Joelle and OLaughlin, Michelle and Grillot, Marcus and Baty, Jack and Heath, Sharon and Frater, John L and Nasim, Talat and Link, Daniel C and Tomasson, Michael H and Westervelt, Peter and DiPersio, John F and Mardis, Elaine R and Ley, Timothy J and Wilson, Richard K and Walter, Matthew J
Nature Genetics, ISSN 1061-4036, 01/2012, Volume 44, Issue 1, p. 53
Usage | Gene mutations | Genetic aspects | Research | Nucleotide sequencing | Health aspects | Myelodysplastic syndromes | Risk factors | DNA sequencing
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.